Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Paolo Fina"'
Autor:
Massimo Bani, Paolo Fina, Luigi Ziviani, Stefano Milleri, Emilio Merlo-Pich, Paolo Bettica, Stefano Zanone Poma
Publikováno v:
Journal of Psychopharmacology. 28:491-497
The pharmacological properties of two NK1 antagonists were studied in comparison with a benzodiazepine during a 7% CO2 challenge in a population of healthy volunteers selected for a high sensitivity to the challenge. In total, 19 healthy subjects, pr
Autor:
David M. Baguley, Paolo Fina, Annelize Koch, Don McFerran, Amir Inamdar, Emilio Merlo-Pich, Pauline Kitchiner, Claire Roberts, Odile Dewit
Publikováno v:
Otology & Neurotology. 32:721-727
Objective Tinnitus is a common symptom that demonstrates a significant comorbidity with anxiety and depression. The novel neurokinin-1 receptor antagonist, vestipitant, has anxiolytic properties and a good safety profile. Vestipitant was investigated
Autor:
Nigel Dallow, Paolo Fina
Publikováno v:
Pharmaceutical Statistics. 10:311-317
In early drug development, especially when studying new mechanisms of action or in new disease areas, little is known about the targeted or anticipated treatment effect or variability estimates. Adaptive designs that allow for early stopping but also
Autor:
Monica Fiore, Stefano Zamuner, Michela Peroni, Sofia Fernandes, Sabrina Pagliarusco, Brendan M. Johnson, Laurel M. Adams, Paolo Fina
Publikováno v:
British Journal of Clinical Pharmacology. 70:537-546
AIM To evaluate the impact of single and repeated doses casopitant on the pharmacokinetics of single dose midazolam and nifedipine (CYP3A substrates) in healthy subjects. The effect on debrisoquine metabolism (CYP2D6 substrate) was also assessed.
Autor:
Massimo Gerosa, Fabrizia Giorgiutti, P. Iuzzolino, Paolo Fina, Antonio Nicolato, Albino Bricolo
Publikováno v:
Surgical Neurology. 44:208-223
A retrospective uni-multivariate statistical analysis was performed on 32 prognostic factors to investigate their importance in predicting survival in a series of 76 adult patients with low-grade supratentorial astrocytomas treated over a 13-year per
Autor:
A Andorn, Erica S. Klaassen, Paolo Fina, L Iavarone, Jma van Gerven, Msg Bani, Rwm Zoethout, E.T. te Beek
Publikováno v:
Journal of Psychopharmacology, 26(2), 303-314
GSK598809 is a novel selective dopamine D3 receptor antagonist, currently in development for the treatment of substance abuse and addiction. In a blinded, randomized, placebo-controlled study, effects of single oral doses of 175 mg GSK598809 were eva
Autor:
Stefano, Zamuner, Brendan M, Johnson, Sabrina, Pagliarusco, Paolo, Fina, Michela, Peroni, Monica, Fiore, Laurel M, Adams, Sofia A, Fernandes
Publikováno v:
British journal of clinical pharmacology. 70(4)
To evaluate the impact of single and repeated doses casopitant on the pharmacokinetics of single dose midazolam and nifedipine (CYP3A substrates) in healthy subjects. The effect on debrisoquine metabolism (CYP2D6 substrate) was also assessed.Three op
Publikováno v:
Trends in Pharmacological Sciences. 17:220-222
The co-agonism between glutamate and glycine at the NMDA receptor raises uncertainty about the estimation of the values of dissociation constants for agonists and antagonists and of efficacy for agonists. In this article, Mauro Corsi, Paolo Fina and
Autor:
Sofia Fernandes, Stefano Zamuner, Brendan M. Johnson, Laurel M. Adams, Michela Peroni, Paolo Fina
Publikováno v:
Molecular Cancer Therapeutics. 8:C133-C133
Background: Clinical studies suggest that casopitant, a novel neurokinin-1 receptor antagonist in development for prevention of postoperative and chemotherapy-induced nausea and vomiting (PONV and CINV, respectively), is a mild to moderate inhibitor